Key result
Reweighting the DAPT trial to a contemporary US registry population showed prolonged DAPT no longer reduced stent thrombosis but persistent increased bleeding.
Why the study?
Evolution in stent technology and clinical practice may attenuate the benefit of prolonged DAPT seen in the DAPT Study when applied to contemporary PCI populations.
Does 30 months of DAPT compared to 12 months improve ischemic outcomes without excessive bleeding in a contemporary cohort of patients receiving drug-eluting stents?
Observational (n=577,404)
Yes
Does 30 months of DAPT compared to 12 months improve ischemic outcomes without excessive bleeding in a contemporary cohort of patients receiving drug-eluting stents?
In a contemporary US PCI population, the ischemic benefits of prolonged DAPT observed in the older DAPT Study are attenuated, while the bleeding risks persist, limiting the applicability of the original trial results.
Answers are grounded in this paper and cite their sources.
Attenuated ischemic benefit of prolonged DAPT in contemporary US patients; challenges original trial applicability and leaves optimal duration open.
BACKGROUND: Differences in patient characteristics, changes in treatment algorithms, and advances in medical technology could each influence the applicability of older randomized trial results to contemporary clinical practice. The DAPT Study (Dual Antiplatelet Therapy) found that longer-duration DAPT decreased ischemic events at the expense of greater bleeding, but subsequent evolution in stent technology and clinical practice may attenuate the benefit of prolonged DAPT in a contemporary population. We evaluated whether the DAPT Study population is different from a contemporary population of US patients receiving percutaneous coronary intervention and estimated the treatment effect of extended-duration antiplatelet therapy after percutaneous coronary intervention in this more contemporary cohort. METHODS: We compared the characteristics of drug-eluting stent-treated patients randomly assigned in the DAPT Study to a sample of more contemporary drug-eluting stent-treated patients in the National Cardiovascular Data Registry CathPCI Registry from July 2016 to June 2017. After linking trial and registry data, we used inverse-odds of trial participation weighting to account for patient and procedural characteristics and estimated a contemporary real-world treatment effect of 30 versus 12 months of DAPT after coronary stent procedures. RESULTS: The US drug-eluting stent-treated trial cohort included 8864 DAPT Study patients, and the registry cohort included 568 540 patients. Compared with the trial population, registry patients had more comorbidities and were more likely to present with myocardial infarction and receive 2nd-generation drug-eluting stents. After reweighting trial results to represent the registry population, there was no longer a significant effect of prolonged DAPT on reducing stent thrombosis (reweighted treatment effect: -0.40 [95% CI, -0.99% to 0.15%]), major adverse cardiac and cerebrovascular events (reweighted treatment effect, -0.52 [95% CI, -2.62% to 1.03%]), or myocardial infarction (reweighted treatment effect, -0.97% [95% CI, -2.75% to 0.18%]), but the increase in bleeding with prolonged DAPT persisted (reweighted treatment effect, 2.42% [95% CI, 0.79% to 3.91%]). CONCLUSIONS: The differences between the patients and devices used in contemporary clinical practice compared with the DAPT Study were associated with the attenuation of benefits and greater harms attributable to prolonged DAPT duration. These findings limit the applicability of the average treatment effects from the DAPT Study in modern clinical practice.
No takes yet. Share an insight, caveat, or question.
Butala et al. (2021) conducted an observational in Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (n=577,404). Prolonged dual antiplatelet therapy (DAPT) vs. 12 months of DAPT was evaluated on Stent thrombosis (reweighted treatment effect -0.40%, 95% CI -0.99 to 0.15). Reweighting the DAPT trial to a contemporary US registry population showed prolonged DAPT no longer reduced stent thrombosis but persistent increased bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: